13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001595855
Total reported value
$1.1B
$1.1B
45 檔
21.4%
During the Q1 2025 filing period, Opaleye Management Inc. (CIK: 0001595855) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $1.1B across 45 reported positions.
Opaleye Management Inc. executed strategic sector rebalancing during Q1 2025, establishing 36 new positions while fully exiting 39 holdings and trimming 5 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | HROW | Harrow Inc | Stock-Other | 23.42% | -3.92% | -0.88% | |
| 2 | ETON | Eton Pharmaceuticals Inc | Stock-Other | 8.24% | +0.08% | — | |
| 3 | SNWV | Sanuwave Health Inc | Stock-Other | 7.65% | -1.95% | — | |
| 4 | LQDA | Liquidia CORP | Stock-Other | 7.42% | +5.97% | +33.09% | |
| 5 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 5.78% | -3.42% | -2.00% | |
| 6 | CDXS | Codexis Inc | Stock-Other | 5.69% | -0.07% | +7.47% | |
| 7 | IMNM | Immunome Inc | Stock-Other | 5.32% | — | +74.02% | |
| 8 | TGTX | Tg Therapeutics Inc | Stock-Healthcare | 4.70% | +0.32% | -76.33% | |
| 9 | ARVN | Arvinas Inc | Stock-Other | 3.09% | — | +21.54% | |
| 10 | OCUL | Ocular Therapeutix Inc | Stock-Other | 2.60% | -0.14% | -63.27% | |
| 11 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 1.93% | -0.23% | -17.71% | |
| 12 | TARA | Protara Therapeutic Inc | Stock-Other | 1.64% | — | -5.21% | |
| 13 | DNA | Ginkgo Bioworks Holdings Inc | Stock-Other | 1.52% | — | -0.42% | |
| 14 | GOSS 5 06-01-27Bond | Gossamer Bio Inc | Bond | 1.41% | — | — | |
| 15 | ANIK | Anika Therapeutics Inc | Stock-Other | 1.32% | — | — | |
| 16 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 1.13% | -0.28% | — | |
| 17 | XOMA | Xoma Royalty Corporation | Stock-Other | 1.12% | +0.06% | +1.22% | |
| 18 | TRVI | Trevi Therapeutics Inc | Stock-Other | 1.11% | -0.02% | -65.70% | |
| 19 | PVLA | Palvella Therapeutics Inc | Stock-Other | 1.07% | — | — | |
| 20 | GOSS | Gossamer Bio Inc | Stock-Other | 1.05% | — | -4.51% | |
| 21 | ANAB | Anaptysbio Inc | Stock-Other | 1.04% | — | — | |
| 22 | KPTI 3 10-15-25Bond | Karyopharm Therapeutics | Bond | 1.01% | — | — | |
| 23 | IRON | Disc Medicine Inc | Stock-Other | 0.94% | +2.11% | — | |
| 24 | LRMR | Larimar Therapeutics Inc | Stock-Other | 0.92% | — | — | |
| 25 | CGON | Cg Oncology Inc | Stock-Other | 0.89% | -0.74% | — | |
| 26 | ✓ | Acelyrin Inc | Stock-Other | 0.89% | — | -27.74% | |
| 27 | RCEL | Avita Medical Inc | Stock-Other | 0.80% | — | — | |
| 28 | EPIEUR | Essa Pharma Inc | Stock-Other | 0.78% | — | — | |
| 29 | ZNTL | Zentalis Pharmaceuticals Inc | Stock-Other | 0.70% | +0.18% | +12.31% | |
| 30 | CRGX | Cargo Therapeutics Inc | Stock-Other | 0.60% | — | -11.13% | |
| 31 | ZYME | Zymeworks Inc | Stock-Other | 0.46% | — | — | |
| 32 | ✓ | Biodesix Inc | Stock-Other | 0.45% | — | -6.93% | |
| 33 | STOK | Stoke Therapeutics Inc | Stock-Other | 0.44% | -0.93% | +1100.00% | |
| 34 | MBX | Mbx Biosciences Inc | Stock-Other | 0.41% | +0.28% | — | |
| 35 | OPTNUSD | Optinose Inc | Stock-Other | 0.39% | — | — | |
| 36 | IRD | Opus Genetics Inc | Stock-Other | 0.34% | +0.12% | — | |
| 37 | IBIO | Ibio Inc | Stock-Other | 0.34% | — | — | |
| 38 | KNSA | Kiniksa Pharmaceuticals International, plc | Stock-Other | 0.31% | — | — | |
| 39 | NRIX | Nurix Therapeutics Inc | Stock-Other | 0.30% | — | -69.62% | |
| 40 | RZLT | Rezolute Inc | Stock-Other | 0.30% | +0.44% | — | |
| 41 | SGMOQ | Sangamo Therapeutics Inc | Stock-Other | 0.15% | — | — | |
| 42 | PEPG | Pepgen Inc | Stock-Other | 0.13% | — | +281.82% | |
| 43 | DERM | Journey Medical CORP | Stock-Other | 0.09% | -0.37% | — | |
| 44 | VTYXUSD | Ventyx Biosciences Inc | Stock-Other | 0.05% | — | -32.14% | |
| 45 | ADGM | Adagio Medical Holdings Inc | Stock-Other | 0.02% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | HROW | Harrow Inc | +18.6% | -0.88% | Add |
| 2 | ETON | Eton Pharmaceuticals Inc | +3.4% | — | Trim |
| 3 | CDXS | Codexis Inc | +0.6% | +7.47% | Add |
| 4 | LRMR | Larimar Therapeutics Inc | -0.3% | — | Add |
| 5 | EPIEUR | Essa Pharma Inc | -0.6% | — | Add |
| 6 | XOMA | Xoma Royalty Corporation | -0.8% | +1.22% | Trim |
| 7 | PTGX | Protagonist Therapeutics Inc | -1.3% | — | Trim |
| 8 | TARA | Protara Therapeutic Inc | -2.5% | -5.21% | Trim |
| 9 | OCUL | Ocular Therapeutix Inc | -12.7% | -63.27% | Trim |
| 10 | CMRXEUR | Chimerix Inc | — | EXIT | Sold out |
| 11 | SNWV | Sanuwave Health Inc | — | NEW | New buy |
| 12 | LQDA | Liquidia CORP | — | NEW | New buy |
| 13 | CLDX | Celldex Therapeutics Inc | — | EXIT | Sold out |
| 14 | BBIO | Bridgebio Pharma Inc | — | EXIT | Sold out |
| 15 | RYTM | Rhythm Pharmaceuticals Inc | — | NEW | New buy |
| 16 | STXS | Stereotaxis Inc | — | EXIT | Sold out |
| 17 | IMNM | Immunome Inc | — | NEW | New buy |
| 18 | TGTX | Tg Therapeutics Inc | — | NEW | New buy |
| 19 | ✓ | — | EXIT | Sold out | |
| 20 | KNSA | Kiniksa Pharmaceuticals International, plc | — | EXIT | Sold out |
| 21 | MGNX | Macrogenics Inc | — | EXIT | Sold out |
| 22 | ARVN | Arvinas Inc | — | NEW | New buy |
| 23 | ✓ | — | EXIT | Sold out | |
| 24 | CYTK | Cytokinetics Inc | — | EXIT | Sold out |
| 25 | ✓ | Neoleukin Therapeutics Inc | — | EXIT | Sold out |
| 26 | AFIB | Acutus Medical Inc | — | EXIT | Sold out |
| 27 | KROS | Keros Therapeutics Inc | — | EXIT | Sold out |
| 28 | ✓ | Veralto CORP | — | EXIT | Sold out |
| 29 | ✓ | Proqr Therapeutics N.v. | — | EXIT | Sold out |
| 30 | STRO | Sutro Biopharma, Inc. | — | EXIT | Sold out |
| 31 | ADMSEUR | Adamas Pharmaceuticals Inc | — | EXIT | Sold out |
| 32 | EWTX | Edgewise Therapeutics Inc | — | NEW | New buy |
| 33 | PCVX | Vaxcyte Inc | — | EXIT | Sold out |
| 34 | DCPHEUR | Deciphera Pharmaceuticals In | — | EXIT | Sold out |
| 35 | TELA | Tela Bio Inc | — | EXIT | Sold out |
| 36 | DNA | Ginkgo Bioworks Holdings Inc | — | NEW | New buy |
| 37 | GOSS 5 06-01-27Bond | Gossamer Bio Inc | — | NEW | New buy |
| 38 | MCRB1EUR | Seres Therapeutics Inc | — | EXIT | Sold out |
| 39 | ANIK | Anika Therapeutics Inc | — | NEW | New buy |
| 40 | AXONEUR | Sio Gene Therapies Inc | — | EXIT | Sold out |
| 41 | ✓ | Cm Life Sciences Inc | — | EXIT | Sold out |
| 42 | ✓ | Cerecor Inc | — | EXIT | Sold out |
| 43 | TRVI | Trevi Therapeutics Inc | — | NEW | New buy |
| 44 | PVLA | Palvella Therapeutics Inc | — | NEW | New buy |
| 45 | GOSS | Gossamer Bio Inc | — | NEW | New buy |
| 46 | ANAB | Anaptysbio Inc | — | NEW | New buy |
| 47 | KPTI 3 10-15-25Bond | Karyopharm Therapeutics | — | NEW | New buy |
| 48 | MEIPUSD | Lite Strategy Inc | — | EXIT | Sold out |
| 49 | 0HJQ | Aveo Pharmaceuticals Inc | — | EXIT | Sold out |
| 50 | ✓ | Forma Therapeutics Holdings | — | EXIT | Sold out |
According to official SEC Form 13F filings, Opaleye Management Inc. reported a total U.S. public equity portfolio value of $1.1B across 45 disclosed positions in Q1 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including HROW, ETON, SNWV) accounted for 21.4% of total reported equity market value during Q1 2025.
Top New Position Initiated
SNWV
市值: $34.4M
Top Position Liquidated / Trimmed
CMRXEUR
前期市值: $37.0M
During Q1 2025, Opaleye Management Inc.'s top holdings by market value included HROW (23.4%)、ETON (8.2%)、SNWV (7.7%). The largest single position, HROW, represented 23.4% of total portfolio value.
In Q1 2025, Opaleye Management Inc. made 84 total portfolio adjustments, initiating 36 new buys, adding to 4 positions, trimming 5 holdings, and fully liquidating 39 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.